Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
The Delivery of Nitric Oxide in the Cardiovascular System: Implication for Clinical Diagnosis and Therapy (preprint)
preprints.org; 2021.
Preprint
en Inglés
| PREPRINT-PREPRINTS.ORG | ID: ppzbmed-10.20944.preprints202110.0177.v1
ABSTRACT
Nitric oxide (NO) is a key molecule in cardiovascular homeostasis and its abnormal delivery is highly associated with the occurrence and development of cardiovascular disease (CVD). The assessment and manipulation of NO delivery is crucial to the diagnosis and therapy of CVD, such as endothelial dysfunction, atherosclerotic progression, pulmonary hypertension, and cardiovascular manifestations of Coronavirus (COVID-19). However, due to the low concentration and fast reaction characteristics of NO in cardiovascular system, the clinical applications centered on the NO delivery are challenging. In this tutorial review, we first summarized the methods to estimate the in vivo NO delivery process based on the clinical images and mathematical modeling to assess the endothelial function and vulnerability of atherosclerotic plaque. Then, the emerging bioimaging technologies that have the potential to directly measure the arterial NO concentration were discussed, including the Raman spectroscopy and electrochemical sensor. Aside from the diagnostic methods, therapies aimed at controlling NO delivery to regulate CVD were reviewed, including the inhaled NO therapy to treat the pulmonary hypertension and COVID-19, stem cell therapy and NO-releasing platform to treat endothelial dysfunction and atherosclerosis.
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
PREPRINT-PREPRINTS.ORG
Asunto principal:
Enfermedades Cardiovasculares
/
Neoplasias Primarias Secundarias
/
Aterosclerosis
/
Síndrome Endotelial Iridocorneal
/
Placa Aterosclerótica
/
COVID-19
/
Hipertensión Pulmonar
Idioma:
Inglés
Año:
2021
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS